CJC-1295

The CJC-1295 evidence base cited here is 6 sources — 2 clinical, 3 preclinical, 1 review. Its strongest evidence is human — 2 clinical studies, most recently 2006 ("Teichman et al. — CJC-1295 Pharmacokinetics in Humans"). Regulatory status: Not FDA-approved.

• CJC-1295 without DAC — also called Modified GRF 1-29 (Mod GRF 1-29) — is a short-acting synthetic analog of growth-hormone-releasing hormone (GHRH).
• Its defining feature is a very SHORT half-life (~30 minutes), which produces brief, pulsatile GH release that mimics the body's natural secretion pattern — the opposite design goal of the DAC version.
• That pulsatility is the whole point: it raises GH and IGF-1 without the continuous, non-physiological elevation (and desensitization risk) seen with long-acting analogs.

CJC-1295 without DAC (Mod GRF 1-29) is a stabilized fragment of GHRH that stimulates the pituitary to release growth hormone in natural-style pulses. Where the DAC version is engineered for long, continuous action, the non-DAC variant is deliberately short-acting — it spikes GH and clears quickly, preserving the pulsatile rhythm that normal GH physiology depends on.

It is investigational, not FDA-approved, and everything below is research context rather than medical guidance.

It is a modified GHRH(1-29) peptide — 30 amino acids, ~3,368 Da — with amino-acid substitutions that improve enzymatic stability over native GHRH (about 4× greater receptor affinity and resistance to DPP-4 breakdown, per comparative work), while still clearing rapidly.

Crucially, it does NOT carry the Drug Affinity Complex (DAC) that binds albumin. Without DAC, the half-life stays short (~30 minutes), which is what keeps GH release pulsatile rather than continuous.

Half-life note: the intended, study-supported half-life is ~30 minutes (Teichman et al., 2006). Any source citing a multi-day half-life for the NON-DAC version has almost certainly confused it with the DAC variant — the short half-life is the entire reason the non-DAC form exists.

It binds GHRH receptors on pituitary somatotroph cells, raising intracellular cAMP and triggering a pulse of growth-hormone release. Because it clears in roughly half an hour, GH returns to baseline between doses — preserving the natural pulsatile pattern and avoiding the receptor desensitization that constant stimulation can cause. Adding a GHRP (ipamorelin, GHRP-2/6) amplifies each pulse through a complementary receptor, which is why the two classes are so often paired.

There is no approved dosing. The short half-life means it's dosed more than once daily to create multiple pulses; figures below are research context only.

• Commonly reported: ~100 mcg subcutaneously 1–3× per day
• Often timed on waking, post-workout, and/or before bed (GH pulses align with sleep onset)
• Frequently paired with a GHRP for a larger combined pulse
• Best taken ~30+ minutes away from food (high blood glucose/fat blunts the GH pulse)

• Reconstitute with bacteriostatic water added slowly down the vial wall; swirl gently, never shake; discard if cloudy or particulate.
• Store reconstituted solution at 2–8°C; lyophilized powder has ~2-year stability when kept cold and sealed.
• Avoid pre-mixed/pre-reconstituted solutions — peptide degrades faster in solution. Discolored (yellow/brown) powder is a red flag.

Generally well-tolerated in reports; the most common effect is transient facial flushing or warmth 5–10 minutes after injection. Because it raises GH/IGF-1, monitor blood glucose if diabetic, and it is not advisable with active cancer (growth-promoting signaling), diabetic retinopathy, or severe kidney disease. No human safety data establishes long-term use.

• Teichman et al. (2006) — characterized the GHRH-analog PK, the basis for the ~30-minute non-DAC half-life.
• CJC-1295 vs native GHRH (in vitro + human): ~4× greater receptor affinity and improved enzymatic resistance vs native GHRH.
• GH pulsatility with Mod GRF 1-29 (human, 100 mcg 3×/day, 30 days): preserved natural pulsatility without desensitization.

Not FDA-approved for any use; sold as a research chemical for laboratory use only, not intended for human consumption. GH-axis peptides may also fall under sport anti-doping prohibitions — tested athletes should verify with their governing body.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.